Eybelis ophthalmic solution 0.002%
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Normal Tension Glaucoma
Conditions
Normal Tension Glaucoma, Primary Open-angle Glaucoma, Glaucoma, Suspect, Ocular Hypertension
Trial Timeline
Feb 15, 2022 → Nov 20, 2023
NCT ID
NCT05279716About Eybelis ophthalmic solution 0.002%
Eybelis ophthalmic solution 0.002% is a approved stage product being developed by Santen Pharmaceutical for Normal Tension Glaucoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT05279716. Target conditions include Normal Tension Glaucoma, Primary Open-angle Glaucoma, Glaucoma, Suspect.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05279716 | Approved | UNKNOWN |
Competing Products
20 competing products in Normal Tension Glaucoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Roxadustat | Astellas Pharma | Phase 1 | 33 |
| Donepezil | Eisai | Approved | 85 |
| eribulin mesylate | Eisai | Phase 2 | 52 |
| Lurasidone HCl | Sumitomo Pharma | Phase 1 | 33 |
| Triptorelin | Merck | Pre-clinical | 23 |
| Temozolomide + Vorinostat | Merck | Phase 2 | 52 |
| LDE225 | Novartis | Phase 1 | 33 |
| LDK378 | Novartis | Phase 1 | 33 |
| cyclosporine micro-emulsion | Novartis | Approved | 85 |
| LDK378 | Novartis | Phase 1 | 33 |
| LEE011 | Novartis | Phase 1 | 33 |
| LEE011 | Novartis | Phase 1 | 33 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| filgrastim | Amgen | Pre-clinical | 22 |
| PF-06423264 | Pfizer | Phase 1 | 32 |
| PF-05221304 | Pfizer | Phase 1 | 32 |
| BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose Solution | Bristol Myers Squibb | Phase 1 | 32 |
| tolebrutinib | Sanofi | Phase 1 | 32 |
| Venglustat (GZ402671) | Sanofi | Phase 1 | 32 |
| Rilzabrutinib | Sanofi | Phase 1 | 32 |
Other Products from Santen Pharmaceutical
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77
DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%Phase 3
77